Aarti Drugs Limited (BOM: 524348)
India
· Delayed Price · Currency is INR | Market Cap | 49.63B |
| Revenue (ttm) | 24.23B |
| Net Income (ttm) | 1.57B |
| Shares Out | 91.94M |
| EPS (ttm) | 17.01 |
| PE Ratio | 31.74 |
| Forward PE | 21.25 |
| Dividend | 1.00 (0.19%) |
| Ex-Dividend Date | n/a |
| Volume | 12,230 |
| Open | 559.65 |
| Previous Close | 544.70 |
| Day's Range | 538.30 - 559.65 |
| 52-Week Range | 430.00 - 634.90 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 18, 2024 |
About Aarti Drugs
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, ti... [Read more]
Financial Performance
In 2023, Aarti Drugs's revenue was 25.29 billion, a decrease of -6.90% compared to the previous year's 27.16 billion. Earnings were 1.71 billion, an increase of 3.07%.
Financial StatementsNews
Aarti Drugs announces share buyback at 60% premium
Shares of Aarti Drugs surged over 9% following the buyback announcement.
Aarti Drugs shares surge 10% ahead of board meeting on sixth buyback plan
Aarti Drugs Ltd. has seen its shares rise by 10% in anticipation of an upcoming board meeting to consider a new share buyback. The board is scheduled to meet on August 26, 2024, to discuss the buyback...